PURPOSE: To report the long-term outcome for patients with Stage T1-T2 adenocarcinoma of the prostate definitively irradiated in the prostate-specific antigen (PSA) era. METHODS AND MATERIALS: Nine institutions combined data on 4839 patients with Stage T1b, T1c, and T2 adenocarcinoma of the prostate who had a pretreatment PSA level and had received >or=60 Gy as definitive external beam radiotherapy. No patient had hormonal therapy before treatment failure. The median follow-up was 6.3 years. The end point for outcome analysis was PSA disease-free survival at 5 and 8 years after therapy using the American Society for Therapeutic Radiology and Oncology (ASTRO) failure definition. RESULTS: The PSA disease-free survival rate for the entire group of patients was 59% at 5 years and 53% at 8 years after treatment. For patients who had received >or=70 Gy, these percentages were 61% and 55%. Of the 4839 patients, 1582 had failure by the PSA criteria, 416 had local failure, and 329 had distant failure. The greatest risk of failure was at 1.5-3.5 years after treatment. The failure rate was 3.5-4.5% annually after 5 years, except in patients with Gleason score 8-10 tumors for whom it was 6%. In multivariate analysis for biochemical failure, pretreatment PSA, Gleason score, radiation dose, tumor stage, and treatment year were all significant prognostic factors. The length of follow-up and the effect of backdating as required by the ASTRO failure definition also significantly affected the outcome results. Dose effects were most significant in the intermediate-risk group and to a lesser degree in the high-risk group. No dose effect was seen at 70 or 72 Gy in the low-risk group. CONCLUSION: As follow-up lengthens and outcome data accumulate in the PSA era, we continue to evaluate the efficacy and durability of radiotherapy as definitive therapy for early-stage prostate cancer. Similar studies with higher doses and more contemporary techniques will be necessary to explore more fully the potential of this therapeutic modality.
PURPOSE: To report the long-term outcome for patients with Stage T1-T2 adenocarcinoma of the prostate definitively irradiated in the prostate-specific antigen (PSA) era. METHODS AND MATERIALS: Nine institutions combined data on 4839 patients with Stage T1b, T1c, and T2 adenocarcinoma of the prostate who had a pretreatment PSA level and had received >or=60 Gy as definitive external beam radiotherapy. No patient had hormonal therapy before treatment failure. The median follow-up was 6.3 years. The end point for outcome analysis was PSA disease-free survival at 5 and 8 years after therapy using the American Society for Therapeutic Radiology and Oncology (ASTRO) failure definition. RESULTS: The PSA disease-free survival rate for the entire group of patients was 59% at 5 years and 53% at 8 years after treatment. For patients who had received >or=70 Gy, these percentages were 61% and 55%. Of the 4839 patients, 1582 had failure by the PSA criteria, 416 had local failure, and 329 had distant failure. The greatest risk of failure was at 1.5-3.5 years after treatment. The failure rate was 3.5-4.5% annually after 5 years, except in patients with Gleason score 8-10 tumors for whom it was 6%. In multivariate analysis for biochemical failure, pretreatment PSA, Gleason score, radiation dose, tumor stage, and treatment year were all significant prognostic factors. The length of follow-up and the effect of backdating as required by the ASTRO failure definition also significantly affected the outcome results. Dose effects were most significant in the intermediate-risk group and to a lesser degree in the high-risk group. No dose effect was seen at 70 or 72 Gy in the low-risk group. CONCLUSION: As follow-up lengthens and outcome data accumulate in the PSA era, we continue to evaluate the efficacy and durability of radiotherapy as definitive therapy for early-stage prostate cancer. Similar studies with higher doses and more contemporary techniques will be necessary to explore more fully the potential of this therapeutic modality.
Authors: Matthew S Katz; Jason A Efstathiou; Anthony V D'Amico; Michael W Kattan; Martin G Sanda; Paul L Nguyen; Matthew R Smith; Peter R Carroll; Anthony L Zietman Journal: BJU Int Date: 2010-03-15 Impact factor: 5.588
Authors: Antonio C Westphalen; Galen D Reed; Phillip P Vinh; Christopher Sotto; Daniel B Vigneron; John Kurhanewicz Journal: J Magn Reson Imaging Date: 2012-04-25 Impact factor: 4.813
Authors: Xuehong Deng; Bennett D Elzey; Jean M Poulson; Wallace B Morrison; Song-Chu Ko; Noah M Hahn; Timothy L Ratliff; Chang-Deng Hu Journal: Am J Cancer Res Date: 2011-08-18 Impact factor: 6.166
Authors: Donald P Braun; Digant Gupta; Timothy C Birdsall; Michele Sumner; Edgar D Staren Journal: J Altern Complement Med Date: 2012-10-04 Impact factor: 2.579
Authors: Ryan S Brame; Marco Zaider; Kristen L Zakian; Jason A Koutcher; Amita Shukla-Dave; Victor E Reuter; Michael J Zelefsky; Peter T Scardino; Hedvig Hricak Journal: Int J Radiat Oncol Biol Phys Date: 2008-11-05 Impact factor: 7.038
Authors: Max Peters; Maaike R Moman; Henk G van der Poel; Henk Vergunst; Igle Jan de Jong; Peter L M Vijverberg; Jan J Battermann; Simon Horenblas; Marco van Vulpen Journal: World J Urol Date: 2012-08-18 Impact factor: 4.226